Physician profile
Marlene Pamandanan Jarin
NPI 1609018134
$17,896.24
in general payments reported to CMS, 2019-2025
27 companies · $2,448 in 2025
The $2,448 reported for 2025 was more than what 96% of Adult Medicine providers received nationally (typical 2025 total: $127).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $6,464 · 2020: $956 · 2021: $1,088 · 2022: $1,603 · 2023: $2,507 · 2024: $2,829 · 2025: $2,448.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,784.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,784.47 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $7,565.20 | 2019-2025 | Descovy, Biktarvy |
| Viiv Healthcare Company | $5,578.90 | 2019-2025 | Dovato, Apretude, Cabenuva |
| Janssen Biotech, INC. | $1,022.88 | 2019-2023 | Symtuza |
| Theratechnologies INC. | $639.29 | 2022-2025 | Egrifta, Trogarzo |
| Lilly USA, LLC | $532.93 | 2022-2025 | Mounjaro, Zepbound |
| Merck Sharp & Dohme LLC | $438.00 | 2019-2025 | Pifeltro, Delstrigo, Isentress |
| Janssen Products, Lp | $421.67 | 2019-2021 | |
| Emd Serono, INC. | $361.21 | 2019-2025 | Serostim |
| Glaxosmithkline, LLC. | $197.86 | 2019-2021 | |
| Endo Pharmaceuticals INC. | $144.88 | 2019-2023 | Nascobal |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $139.79 | 2019-2024 | Xifaxan |
| Exact Sciences Corporation | $128.59 | 2023-2025 | Cologuard Collection Kit |
| Idorsia Pharmaceuticals US INC | $103.94 | 2022-2024 | Quviviq |
| Pfizer INC. | $99.83 | 2019-2024 | |
| Novo Nordisk INC | $79.10 | 2023-2025 | Rybelsus, Ozempic, Wegovy |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Insulet Corporation | $57.64 | 2025 | Omnipod |
| Medtronic, INC. | $56.67 | 2025 | Closurefast |
| Mylan Pharmaceuticals INC. | $55.37 | 2019-2020 | |
| Napo Pharmaceuticals INC | $54.58 | 2019-2025 | Mytesi |
| Vbi Vaccine (Delaware) INC. | $47.52 | 2022-2023 | Prehevbrio |
| Abbvie INC. | $41.12 | 2022-2023 | |
| Kowa Pharmaceuticals America, INC. | $33.59 | 2020-2024 | Zoryve |
| Dynavax Technologies Corporation | $26.65 | 2020-2022 | |
| Amgen INC. | $20.39 | 2019 | |
| Antares Pharma, INC. | $18.74 | 2019 | |
| Amarin Pharma, INC. | $17.34 | 2019 | |
| Aytu Biopharma, INC. | $12.56 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Marlene Jarin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.